1.
Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, de Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. haematol [Internet]. 2021Aug.19 [cited 2021Sep.17];. Available from: https://haematologica.org/article/view/haematol.2021.279802